Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2016

View Archived Issues

Kezar Life Sciences begins phase I study of its immunoproteasome inhibitor

Aphios obtains funding from NIAID to develop cure for HIV/AIDS

C3 may be useful as a biomarker to monitor ERT efficacy in Fabry disease

New transgenic model to assess target engagement of tau gene silencing therapies in live mice

Phase I data for CAR-modified T-cell immunotherapy in patients with non-Hodgkin's lymphoma

Azevan reports promising phase II data for SRX-246 in intermittent explosive disorder

Merck KGaA joins project to improve vaccine purification processes

FDA approves Shire's Cuvitru for primary immunodeficiency

Allele Biotechnology and Pharmaceuticals awarded SBIR grant from NHLBI

Neural Analytics receives NIH grant to develop brain diagnostic and monitoring platform

Launch of Relay Therapeutics with novel drug discovery platform focused on protein motion

Bayer and Monsanto sign definitive merger agreement

Aerie reports encouraging data from first registration trial of Roclatan

Allergan to acquire Vitae Pharmaceuticals and strengthen its dermatology product pipeline

Inhibikase Therapeutics cleared to conduct clinical studies of ABL inhibitors in Parkinson's disease

SELLAS Life Sciences enters CRADA to develop AML-MRD assay

Lenvatinib approved in E.U. for renal cell carcinoma

New gene silencing model confirms the XPO1 gene as a target for treating heart failure

KCa3.1 channel blockade shows promise as a therapeutic target in pulmonary fibrosis

FDA committee says studies of apaziquone do not show evidence of treatment effect

Bexion initiates phase I trial of BXQ-350 for advanced solid tumors

Basilea partners with Asahi Kasei Pharma for isavuconazole in Japan

Research indicates AQP1 as potential therapeutic target for pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...